# Synthesis of Superconducting Phase of La$_{0.5}$Ce$_{0.5}$H$_{10}$ at High Pressures

Preprint · Ge Huang, Tao Luo, Philip Dalladay-Simpson, Liu-Cheng Chen, Zi-Yu Cao, Di Peng, Federico A. Gorelli, Guo-Hua Zhong, Hai-Qing Lin, Xiao-Jia Chen

- Archive id: arxiv:2208.05199
- Published: 2022-08-10
- arXiv: https://arxiv.org/abs/2208.05199
- Source URL: https://arxiv.org/abs/2208.05199
- PDF: https://arxiv.org/pdf/2208.05199
- Provenance: arxiv

## Abstract

Clathrate hydride \\emph{Fm}\\={3}\\emph{m}-LaH$\_{10}$ has been proven as the most extraordinary superconductor with the critical temperature $T\_c$ above 250 K upon compression of hundreds of GPa in recent years. A general hope is to reduce the stabilization pressure and maintain the high $T\_c$ value of the specific phase in LaH$\_{10}$. However, strong structural instability distorts \\emph{Fm}\\={3}\\emph{m} structure and leads to a rapid decrease of $T\_c$ at low pressures. Here, we investigate the phase stability and superconducting behaviors of \\emph{Fm}\\={3}\\emph{m}-LaH$\_{10}$ with enhanced chemical pre-compression through partly replacing La by Ce atoms from both experiments and calculations. For explicitly characterizing the synthesized hydride, we choose lanthanum-cerium alloy with stoichiometry composition of 1:1. X-ray diffraction and Raman scattering measurements reveal the stabilization of \\emph{Fm}\\={3}\\emph{m}-La$\_{0.5}$Ce$\_{0.5}$H$\_{10}$ in the pressure range of 140-160 GPa. Superconductivity with $T\_c$ of 175$\\pm$2 K at 155 GPa is confirmed with the observation of the zero-resistivity state and supported by the theoretical calculations. These findings provide applicability in the future explorations for a large variety of hydrogen-rich hydrides.

_Abstract reproduced under CC0-1.0 (arXiv descriptive metadata)._

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.